|
GB0000564D0
(en)
|
2000-01-11 |
2000-03-01 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
WO2002083139A1
(en)
|
2001-04-10 |
2002-10-24 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
|
US6960584B2
(en)
|
2001-04-10 |
2005-11-01 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
|
WO2002083140A1
(en)
|
2001-04-10 |
2002-10-24 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
|
DE60315876T2
(de)
*
|
2002-11-28 |
2008-05-21 |
Neurosearch A/S |
Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
|
|
WO2006061428A2
(en)
*
|
2004-12-10 |
2006-06-15 |
Universität Zürich |
Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
|
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
WO2008030651A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
HRP20140195T1
(hr)
*
|
2008-08-29 |
2014-04-11 |
Concert Pharmaceuticals Inc. |
Supstituirani derivati triazolopiridazina
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
EP2454259A1
(en)
|
2009-06-23 |
2012-05-23 |
Concert Pharmaceuticals Inc. |
Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
|
|
US8278460B2
(en)
|
2009-10-15 |
2012-10-02 |
Concert Pharmaceuticals, Inc. |
Substituted benzimidazoles
|
|
US20150099753A1
(en)
*
|
2012-05-11 |
2015-04-09 |
Concert Pharmaceuticals Inc. |
Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
|
|
JP2015516440A
(ja)
*
|
2012-05-11 |
2015-06-11 |
コンサート ファーマシューティカルズ インコーポレイテッド |
7−(tert−ブチル−d9)−3−(2,5−ジフルオロフェニル)−6−((1−メチル−1H−1,2,4−トリアゾール−5−イル)メトキシ)−[1,2,4]トリアゾロ[4,3−b]ピリダジンの2型多形
|
|
WO2013170241A1
(en)
*
|
2012-05-11 |
2013-11-14 |
Concert Pharmaceuticals, Inc. |
Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine
|
|
WO2015095549A1
(en)
*
|
2013-12-18 |
2015-06-25 |
Concert Pharmaceuticals, Inc. |
Dosage regimen for gabaa receptor subtype selective drug
|
|
HUE060943T2
(hu)
*
|
2018-09-13 |
2023-04-28 |
Saniona As |
A gaba A receptor ligandum
|
|
AU2023258030A1
(en)
*
|
2022-04-20 |
2024-10-17 |
Engrail Therapeutics, Inc. |
Gabaa receptor modulator salts, particles, and uses thereof
|
|
CN115837022B
(zh)
*
|
2023-02-20 |
2023-04-25 |
中山大学附属第八医院(深圳福田) |
1,2,4三唑并4,3-b哒嗪衍生物在制备抗衰老药物中的应用
|
|
AU2024411621A1
(en)
|
2023-12-27 |
2026-06-18 |
Saniona A/S |
A gabaa receptor ligand and the use thereof in medicine, in particular in the treatment of epilepsy
|